Mobile

This study will test an experimental drug called GS-9883/emtricitabine/tenofovir alafenamide (GS-9883/F/TAF) for the treatment of HIV-1 infection. The purpose of this study is to evaluate safety, and ...

Update Il y a 4 ans
Reference: EUCTR2015-003988-10

This study will test an experimental drug called GS-9883/emtricitabine/tenofovir alafenamide (GS-9883/F/TAF) for the treatment of HIV-1 infection. The purpose of this study is to evaluate safety, and to determine whether GS-9883/F/TAF as a fixed dose combination maintains the control of HIV-1 infection effectively compared to treatment with dolutegravir (DTG) (trade name Tivicay) and emtricitabine/tenofovir alafenamide (F/TAF)

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

To evaluate the efficacy of a fixed dose combination (FDC) containing GS-9883/emtricitabine/tenofovir alafenamide (GS-9883/F/TAF) versus dolutegravir (DTG) + a FDC containing emtricitabine/tenofovir alafenamide (F/TAF) in HIV-1 infected, antiretroviral treatment-naïve adult subjects as determined by the achievement of HIV-1 RNA <50 copies/mL at Week 48

Inclusion criteria

  • Human Immunodeficiency Virus (HIV-1) Infection

Links